Patents by Inventor Taylor H. Schreiber

Taylor H. Schreiber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for in vivo expansion of T regulatory cells
    Patent number: 10934364
    Abstract: Compositions specific for TNF-receptor superfamily member 25 (TNFRSF25, DR3) modulate the immune re-sponse by regulating T regulatory cells.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: March 2, 2021
    Assignee: University of Miami
    Inventors: Eckhard R. Podack, Taylor H. Schreiber, Dietlinde-Maria Wolf
  • ANTI-TNFRSF25 ANTIBODIES
    Publication number: 20210017287
    Abstract: Anti-TNFRSF25 antibodies and variants thereof, including those that bind to an epitope in the region of amino acids 48-71, are disclosed. Also contemplated are uses of the antibodies in research, diagnostic, and therapeutic applications.
    Type: Application
    Filed: May 14, 2020
    Publication date: January 21, 2021
    Inventors: Taylor H. Schreiber, Jeff T. Hutchins
  • HUMAN TNFRSF25 ANTIBODY
    Publication number: 20200392238
    Abstract: Antibodies and antigen binding fragments that bind specifically to TNFRSF25 are provided herein. Methods for using the antibodies and antigen binding fragments to, for example, stimulate proliferation of human T cells (e.g., CD8+ T cells) and to treat cancer patients also are provided.
    Type: Application
    Filed: May 14, 2020
    Publication date: December 17, 2020
    Inventor: Taylor H. SCHREIBER
  • Anti-TNFRSF25 antibodies
    Patent number: 10683359
    Abstract: Anti-TNFRSF25 antibodies and variants thereof, including those that bind to an epitope in the region of amino acids 48-71, are disclosed. Also contemplated are uses of the antibodies in research, diagnostic, and therapeutic applications.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: June 16, 2020
    Assignee: Pelican Therapeutics, Inc.
    Inventors: Taylor H. Schreiber, Jeff T. Hutchins
  • Human TNFRSF25 antibody
    Patent number: 10683358
    Abstract: Antibodies and antigen binding fragments that bind specifically to TNFRSF25 are provided herein. Methods for using the antibodies and antigen binding fragments to, for example, stimulate proliferation of human T cells (e.g., CD8+ T cells) and to treat cancer patients also are provided.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: June 16, 2020
    Assignee: Pelican Therapeutics, Inc.
    Inventor: Taylor H. Schreiber
  • ANTI-TNFRSF25 ANTIBODIES
    Publication number: 20180312599
    Abstract: Anti-TNFRSF25 antibodies and variants thereof, including those that bind to an epitope in the region of amino acids 48-71, are disclosed. Also contemplated are uses of the antibodies in research, diagnostic, and therapeutic applications.
    Type: Application
    Filed: April 27, 2018
    Publication date: November 1, 2018
    Inventors: Taylor H. Schreiber, Jeff T. Hutchins
  • HUMAN TNFRSF25 ANTIBODY
    Publication number: 20180312598
    Abstract: Antibodies and antigen binding fragments that bind specifically to TNFRSF25 are provided herein. Methods for using the antibodies and antigen binding fragments to, for example, stimulate proliferation of human T cells (e.g., CD8+ T cells) and to treat cancer patients also are provided.
    Type: Application
    Filed: April 27, 2018
    Publication date: November 1, 2018
    Inventor: Taylor H. Schreiber
  • Method for In Vivo Expansion of T Regulatory Cells
    Publication number: 20180230226
    Abstract: Compositions specific for TNF-receptor superfamily member 25 (TNFRSF25, DR3) modulate the immune re-sponse by regulating T regulatory cells.
    Type: Application
    Filed: April 11, 2018
    Publication date: August 16, 2018
    Inventors: Eckhard R. Podack, Taylor H. Schreiber, Dietlinde-Maria Wolf
  • Anti-TNFRSF25 antibodies
    Patent number: 10005843
    Abstract: Anti-TNFRSF25 antibodies and variants thereof, including those that bind to an epitope in the region of amino acids 48-71, are disclosed. Also contemplated are uses of the antibodies in research, diagnostic, and therapeutic applications.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: June 26, 2018
    Assignee: PELICAN THERAPEUTICS, INC.
    Inventors: Taylor H. Schreiber, Jeff T. Hutchins
  • Human TNFRSF25 antibody
    Patent number: 9982057
    Abstract: Antibodies and antigen binding fragments that bind specifically to TNFRSF25 are provided herein. Methods for using the antibodies and antigen binding fragments to, for example, stimulate proliferation of human T cells (e.g., CD8+ T cells) and to treat cancer patients also are provided.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: May 29, 2018
    Assignee: PELICAN THERAPEUTICS, INC.
    Inventor: Taylor H. Schreiber
  • HUMAN TNFRSF25 ANTIBODY
    Publication number: 20170362329
    Abstract: Antibodies and antigen binding fragments that bind specifically to TNFRSF25 are provided herein. Methods for using the antibodies and antigen binding fragments to, for example, stimulate proliferation of human T cells (e.g., CD8+ T cells) and to treat cancer patients also are provided.
    Type: Application
    Filed: November 17, 2015
    Publication date: December 21, 2017
    Inventor: Taylor H. Schreiber
  • ANTI-TNFRSF25 ANTIBODIES
    Publication number: 20170355773
    Abstract: Anti-TNFRSF25 antibodies and variants thereof, including those that bind to an epitope in the region of amino acids 48-71, are disclosed. Also contemplated are uses of the antibodies in research, diagnostic, and therapeutic applications.
    Type: Application
    Filed: June 9, 2017
    Publication date: December 14, 2017
    Inventors: Taylor H. Schreiber, Jeff T. Hutchins
  • Method for In Vivo Expansion of T Regulatory Cells
    Publication number: 20170226218
    Abstract: Compositions specific for TNF-receptor superfamily member 25 (TNFRSF25, DR3) modulate the immune response by regulating T regulatory cells.
    Type: Application
    Filed: November 21, 2016
    Publication date: August 10, 2017
    Inventors: Eckhard R. Podack, Taylor H. Schreiber, Dietlinde-Maria Wolf
  • Compositions comprising TL1A-Ig fusion protein for the regulation of T regulatory cells, and methods for their use
    Patent number: 9603925
    Abstract: Compositions comprising TL1A-Ig fusion proteins and methods of their use, e.g., for the treatment of diseases and disorders associated with antigen-specific immune responses, are described. Also described are combination therapies that include the administration of a TNFRSF25 agonist and an interleukin (e.g., IL-2) and/or an mTOR inhibitor (e.g., rapamycin).
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: March 28, 2017
    Assignee: University of Miami
    Inventors: Eckhard R. Podack, Taylor H. Schreiber, Samia Q. Khan
  • Compositions comprising TL1A-Ig fusion protein for the regulation of T regulatory cells, and methods for their use
    Patent number: 9468677
    Abstract: Compositions comprising TL1A-Ig fusion proteins and methods of their use, e.g., for the treatment of diseases and disorders associated with antigen-specific immune responses, are described. Also described are combination therapies that include the administration of a TNFRSF25 agonist and an interleukin (e.g., IL-2) and/or an mTOR inhibitor (e.g., rapamycin).
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: October 18, 2016
    Assignee: University of Miami
    Inventors: Eckhard R. Podack, Taylor H. Schreiber, Samia Q. Khan
  • Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein
    Publication number: 20140286897
    Abstract: Compositions comprising TL1A-Ig fusion proteins and methods of their use, e.g., for the treatment of diseases and disorders associated with antigen-specific immune responses, are described. Also described are combination therapies that include the administration of a TNFRSF25 agonist and an interleukin (e.g., IL-2) and/or an mTOR inhibitor (e.g., rapamycin).
    Type: Application
    Filed: February 20, 2014
    Publication date: September 25, 2014
    Applicant: University of Miami
    Inventors: Eckhard R. Podack, Taylor H. Schreiber, Samia Q. Khan
  • Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein
    Publication number: 20140193410
    Abstract: Compositions comprising TL1A-Ig fusion proteins and methods of their use, e.g., for the treatment of diseases and disorders associated with antigen-specific immune responses, are described. Also described are combination therapies that include the administration of a TNFRSF25 agonist and an interleukin (e.g., IL-2) and/or an mTOR inhibitor (e.g., rapamycin).
    Type: Application
    Filed: January 9, 2014
    Publication date: July 10, 2014
    Applicant: University of Miami
    Inventors: Eckhard R. Podack, Taylor H. Schreiber, Samia Q. Khan
  • Compositions comprising TLIA-Ig fusion protein for the regulation of T regulatory cells, and methods for their use
    Patent number: RE48599
    Abstract: Compositions comprising TL1A-Ig fusion proteins and methods of their use, e.g., for the treatment of diseases and disorders associated with antigen-specific immune responses, are described. Also described are combination therapies that include the administration of a TNFRSF25 agonist and an interleukin (e.g., IL-2) and/or an mTOR inhibitor (e.g., rapamycin).
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: June 22, 2021
    Assignee: University of Miami
    Inventors: Eckhard R. Podack, Taylor H. Schreiber, Samia Q. Khan